News

The company’s ANDA product is a generic version of AstraZeneca and Bristol-Myers Squibb’s Onglyza, which is indicated as an adjunct to diet and exercise to improve glycemic control

The company secured exclusive global OTC rights to NEXIUM from British firm AstraZeneca in August 2012. Nexium 24HR (esomeprazole 20mg) was approved by the US Food and Drug

Solara Labs Founder & CEO, Dr. J. Rocca, remarked, "I am thrilled to bring our great-tasting, all-natural melts to the Bariatric community. The BariMelts brand represents our finest

The products covered under the purchase include Restylane, Perlane and Emervel, which are used to fill wrinkles and increase the fullness of lips. The purchase also covers Dysport

Earlier in 2014, a Final Appraisal Determination (FAD) was issued, which concluded Lemtrada is a cost-effective use of NHS resources for MS treatment, and formed the basis of

MGD010 incorporates MacroGenics’ proprietary platform for Dual-Affinity Re-Targeting (DART) to simultaneously engage CD32B and CD79B, which are two B-cell surface proteins. Currently, MGD010 is in pre-clinical development for

The evaluation of BMS’ investigational PD-1 immune checkpoint inhibitor, nivolumab, and Incyte’s oral indoleamine dioxygenase-1 (IDO1) inhibitor, INCB24360, will be done in a Phase I/II trial. Multiple tumor

Probodies are monoclonal antibodies that are selectively activated within the cancer microenvironment, focusing the activity of therapeutic antibodies to tumors and sparing healthy tissue. The unique selectivity of

The notice of allowance for US Patent Application No. 13/258,808 entitled Depot Systems Comprising Glatiramer or Pharmacologically Acceptable Salt Thereof, also awarded additional claims to an earlier patent